Pharmacells Ltd have licensed in a Californian technology that allows them to isolate, store and supply an unusually immature, pre-differentiated stem cell line. They are aiming to offer the World’s first commercially viable adult stem banking product suite. In addition, they have the ability to accelerate scientific research by supplying “their” cell line into appropriate global research projects.

 After going through the usual paths to finding business funding, Pharmacells got in touch with CBAN and explained the predicament that they were in. Two different bodies had offered their full funding round but the terms where very strict and they felt that they would be forced to devote too much time to appeasing their shareholders.

 For this reason, they contacted DLA Piper LLP, the World’s largest legal form and engaged them in a project to create legal “heads of terms” that would provide an umbrella for a number of smaller, private investors.

 CBAN was an integral part in finding those investors and Pharmacells now boasts six smaller investors some with very appropriate experience, one of whom is now a board member and crucial part in the Pharmacells business plan.

 They’re close to securing a match funding round from Scottish Enterprise and the European Union and they plan to launch to the UK market in Summer 2010 and Worldwide in 2011.

 CBAN is very proud to have been of assistance and we believe that Pharmacells and their team have what it takes to be a huge success in a very demanding field.